Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
SEC Accession No. 0001140361-16-060703
Filing Date
2016-04-08
Accepted
2016-04-08 17:23:59
Documents
2
Period of Report
2016-04-06

Document Format Files

Seq Description Document Type Size
1 FORM 3/A doc1.html 3/A  
1 FORM 3/A doc1.xml 3/A 6165
2 poarehm.htm EX-24 7019
  Complete submission text file 0001140361-16-060703.txt   15448
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 3/A | Act: 34 | File No.: 001-37722 | Film No.: 161563473
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Reporting) CIK: 0001297709 (see all company filings)

State of Incorp.: D0 | Fiscal Year End: 1231
Type: 3/A | Act: 34 | File No.: 001-37722 | Film No.: 161563472

Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations